Raymond James Financial
GOSS icon

Raymond James Financial’s Gossamer Bio GOSS Stock Holding History

Raymond James Financial’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed -$332 – 5682
2025
Q2 		$332 Buy
+3
New +$262 ﹤0.01% 6726

Other funds holding GOSS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Raymond James Financial's GOSS Position: Q3 2025 in Review

Raymond James Financial sold out of Gossamer Bio (GOSS) in Q3 2025, closing a stake of 3 shares — an estimated $332 sold.

Raymond James Financial first reported a position in GOSS in Q2 2025 and held it in 1 quarter. The position peaked at $332 in Q2 2025. 162 funds tracked by Wall St. Rank hold GOSS as of Q3 2025.

  • Raymond James Financial reported no remaining Gossamer Bio position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 3 Gossamer Bio shares in Q3 2025, an estimated $332.
  • Raymond James Financial first reported a position in Gossamer Bio in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Gossamer Bio position peaked at $332 in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Gossamer Bio as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.